Cellectar Biosciences Signs Multi-Year Supply Agreement with Ionetix for Key Radioisotopes
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 16 2025
0mins
Source: Newsfilter
- Supply Agreement Signed: Cellectar Biosciences has entered into a multi-year supply agreement with Ionetix to secure clinical and commercial-scale supplies of Ac-225 and At-211 radioisotopes, which will support clinical trials and potential commercialization of targeted alpha therapy candidates.
- Platform Technology Advantage: Cellectar's Phospholipid Drug Conjugate platform technology effectively delivers isotopes directly to tumor cells, and the combination of Ac-225 and At-211 enhances its potential application in treating challenging solid tumors like pancreatic cancer.
- Production Capacity Expansion: Ionetix is installing a second cyclotron at its Michigan facility dedicated to commercial-scale production of Ac-225 and At-211, addressing the growing market demand and ensuring a steady supply for Cellectar's drug development pipeline.
- Strategic Implications: This collaboration not only provides Cellectar with a reliable supply of high-quality isotopes but also propels the expansion of its radiotherapeutic pipeline, further solidifying its market position in cancer treatment.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CLRB?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CLRB
About CLRB
Cellectar Biosciences, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of drugs for treatment of cancer. The Company, through its phospholipid ether drug conjugate (PDC) delivery platform, is focused on developing PDCs that are designed to specifically target cancer cells. Its PDC platform possesses the potential for the discovery and development of cancer-targeting treatments, and it plans to develop PDCs both independently and through research and development collaborations. Its lead programs are: Iopofosine I 131 (iopofosine), a beta-emitting iodine-131-based program which has been studied extensively; CLR 121225, an actinium-225-based program; and CLR 121125, an iodine-125 Auger-emitting program. Iopofosine evaluation is ongoing in a Phase IIb study in r/r multiple myeloma and central nervous system lymphoma patients and the CLOVER-2 Phase Ib study for pediatric patients with high grade gliomas.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Bark Inc (BARK) Shares Surge 19.9% on Acquisition Proposal from Great Dane
- Acquisition Proposal: Great Dane's submission of a non-binding acquisition letter to Bark Inc has led to a 19.9% surge in Bark's pre-market share price to $0.74, indicating strong market enthusiasm for the potential acquisition.
- Market Reaction: The significant rise in Bark Inc's stock price reflects investor optimism regarding the company's future, which may also attract more investor attention and enhance market liquidity for the stock.
- Industry Dynamics: In pre-market trading, Signing Day Sports Inc saw a 43.7% increase, while Ping An Biomedical Co Ltd rose 34.3%, highlighting strong market interest in the biotech and sports sectors, which could influence Bark Inc's market positioning.
- Investor Confidence: The rebound in Bark Inc's stock price may bolster investor confidence in the company, especially after recent market volatility, as the acquisition proposal provides new momentum for future growth.
Continue Reading
Cellectar Plans to Submit iopofosine I 131 for European Approval in 3Q 2026
- Regulatory Milestone: Cellectar plans to submit a Conditional Marketing Authorization application for iopofosine I 131 to the EMA in 3Q 2026, with potential approval in early 2027, positioning the company to capture significant market share among WM patients in Europe.
- Clinical Advancement: The company anticipates dosing the first patients in a Phase 1b study of CLR 125 for triple-negative breast cancer in 1Q 2026, with interim data expected in mid-2026, further validating its therapeutic potential in a challenging market.
- Funding Support: Cellectar raised approximately $15.2 million through financings and warrant exercises to support pipeline development and regulatory milestones, ensuring its continued growth in the competitive biopharmaceutical landscape.
- Strategic Showcase: Cellectar will highlight its 2026 strategic initiatives at the upcoming Biotech Showcase, emphasizing its innovations in cancer treatment and market expansion potential, thereby boosting investor confidence.
Continue Reading